Printer Friendly

Cancer drug hope for eye diseases.

DRUGS USED to treat leukaemia could offer a new target for treating the abnormal blood vessels which form in many blinding conditions, such as age-related macular degeneration and diabetic retinopathy.

Researchers from University College London (UCL) found that imatinib, a drug used to treat leukaemia, inhibited angiogenesis--the growth of abnormal blood vessels.

Professor Christina Ruhrberg, of the UCL Institute of Ophthalmology, who led the research, told Medical Xpress: "We discovered an alternative mechanism that regulates blood vessel growth and does not depend on VEGF."

Patients take imatinib orally, offering hope that an anti-angiogenic treatment could be delivered systemically through tablets rather than by anti-VEGF eye injections.

COPYRIGHT 2014 Ten Alps Publishing
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Optometry Today
Article Type:Brief article
Geographic Code:4EUUK
Date:Jun 6, 2014
Words:106
Previous Article:Blood pressure drugs associated with AMD risk.
Next Article:Practice business developers merge.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters